Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Reduced price
Chronic Lymphocytic Leukemia, An Issue of Hematology/Oncology Clinics of North America

Chronic Lymphocytic Leukemia, An Issue of Hematology/Oncology Clinics of North America

9780323896924
PRINT ON DEMAND - DELIVERY CAN TAKE UP TO 14 DAYS
483.79 zł
411.22 zł Save 72.57 zł Tax included
Lowest price within 30 days before promotion: 411.22 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DHL, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description

This issue of Hematology/Oncology Clinics, guest edited by Dr. Jennifer R. Brown?, will focus on Chronic Lymphocytic Leukemia. This issue is one of six sel‎ected each year by our series consulting editors, Dr. George P. Canellos and Dr. Edward J. Benz. Topics discussed in this issue will include:: Chronic Lymphocytic Leukemia:: Do We Know the Cell of Origin Yet?; Significance of BCR Stereotypy; Prognostic and Predictive Implications of Cytogenetics and Genomics; Role of Epigenetics in Chronic Lymphocytic Leukemia; Genomics of Resistance to Targeted Therapies; First Line Therapy for Chronic Lymphocytic Leukemia; The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia Therapy; BTK Inhibitors; Minimal Residual Disease; Should Undetectable MRD Be the Goal of Chronic Lymphocytic Leukemia Therapy?; Management of Chronic Lymphocytic Leukemia after Progression on BTK Inhibitors; Role of PI3K Inhibitors in Chronic Lymphocytic Leukemia; Can We Restore the Immunodeficiency of Chronic Lymphocytic Leukemia?; and Immune Therapy for Chronic Lymphocytic Leukemia

Product Details
Elsevier
91675
9780323896924
9780323896924

Data sheet

Publication date
2021
Issue number
1
Cover
hard cover
Pages count
240
Dimensions (mm)
152 x 229
Weight (g)
480
  • Potential Relevance of B-cell Maturation Pathways in Defining the Cell(s) of Origin for Chronic Lymphocytic LeukemiaThe Significance of B-cell Receptor Stereotypy in Chronic Lymphocytic Leukemia: Biological and Clinical ImplicationsPrognostic and Predictive Implications of Cytogenetics and GenomicsGenomics of Resistance to Targeted TherapiesFirst-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and BeyondBruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond IbrutinibShould Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Brutons Tyrosine Kinase InhibitorsThe Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic LeukemiaCan Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond
Comments (0)

  • Frequently purchased together

    No products available